European Review for Medical and Pharmacological Sciences 2017; 21: 5859-5867

Hepatitis C-related hepatocellular carcinoma: diagnostic and therapeutic management in HIV-patients

F. D'ALEO[1], M. CECCARELLI[1], E. VENANZI RULLO[1], A. FACCIOLÀ[1], M. DI ROSA[2], M.R. PINZONE[3], F. CONDORELLI[4], G. VISALLI[5], I. PICERNO[5], M. BERRETTA[6], G.F. PELLICANÒ[7], G. NUNNARI[1]

[1]Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, University of Messina, Messina, Italy
[2]Department of Biomedical and Biotechnological Sciences, Human Anatomy and Histology Section, University of Catania, Catania, Italy
[3]Department of Pathology and Laboratory Medicine, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
[4]Department of Pharmacological Sciences, Università del Piemonte Orientale "A. Avogadro", Novara, Italy
[5]Department of Biomedical and Dental Sciences and Morpho Functional Imaging, University of Messina, Messina, Italy
[6]Department of Medical Oncology A, National Cancer Institute of Aviano, Aviano, Italy
[7]Department of Human Pathology of the Adult and the Developmental Age "G. Barresi", Unit of Infectious Diseases, University of Messina, Messina, Italy

Abstract. – The efficacy of the current HIV therapy has led to increased survival and prolongation of the average life expectancy of people living with HIV (PLWH), as well as the emergence of comorbidities and non-AIDS related cancer. Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. Current evidence suggests that HCC is an important cause of morbidity and mortality in HIV infected patients. In fact, HCC prevalence rate is indeed higher with respect to the general population average. In this paper, we review the diagnostic and therapeutic management of Hepatitis C-related hepatocellular carcinoma in HCV-HIV co-infected patients. Several therapeutic options are available depending on several factors as HCC stage, liver functions, comorbidities and they have been divided into three groups: potentially curative, proven effective but not curative, and unproven or ineffective therapy. In HIV-infected patients, surgical options are preferred compared to non-surgical therapies. Further studies, especially multicenter ones, are needed in order to define the most appropriate, evidence-based therapeutic approach to PLWH suffering from HCC. It also appears necessary to develop appropriate care guidelines for PLWH.

Key Words:
Hepatitis C virus, HCV, Hepatocellular carcinoma, HCC, HIV.

Introduction

Due to the improvement in current HIV therapy effectiveness, the scientific community has nowadays to deal with problems related to ageing and prolongation of the average life expectancy of people living with HIV (PLWH)[1-9,10]. Hepatitis C virus (HCV) and hepatitis B virus (HBV) infections are more frequent in PLWH than they are in general population, and with a more aggressive development. It appears that hepatocellular carcinoma (HCC) is becoming a huge problem for HIV-positive patients[11-18]. Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. With more than 740,000 new cases/year, it is the sixth most common cancer worldwide[19-21] and the second most common cause of cancer-related death. Only in the United States during the last two decades the incidence of HCC has doubled, causing the death of more than 16,000 men and 8,000 women[21]. Although we assisted to an increased incidence of the HCC in the developed world, the majority of cases occur in Asia and Africa. Chronic viral hepatitis B and C are the most common causes of chronic hepatitis in the world potentially leading to cirrhosis and HCC[21,22]. Thus, the differences in the incidence of HCC linked to geography

Corresponding Author: Giuseppe Nunnari, MD, Ph.D; e-mail: gnunnari@unime.it

are related to the different prevalence of its major risk factors: chronic viral hepatitis B (HBV) and C (HCV), HIV co-infection, alcohol consumption and abuse, smoke and diabetes, higher testosterone levels, aflatoxin produced by *Aspergillus* species, metabolic and genetic diseases such as hemochromatosis, Wilson's disease, α-1 antitrypsin disease, glycogen-storage disease, and porphyria[22]. As for HCV-infection, which is estimated to affect more than 150 million people globally, six major genotypes have been identified worldwide[21,23,24]. Current evidence suggests that HCC is an important cause of morbidity and mortality in HIV infected patients: the HCC prevalence rate in HIV positive patients is indeed higher with respect to the general population average[17,25].

In 2017 FDA and EMA agreed that every single person infected with HCV needs to be treated with Direct-Acting Antivirals (DAAs), and it was considered a huge step forward in the direction of the eradication of HCV infection. However, later in this same year we had the first reports about HCCs appearance after completion of a treatment with DAAs. Therefore, it is still discussed if DAAs and the achievement of sustained virologic response (SVR) are enough to stop the development of HCC[16,26-30].

In this report, we review the diagnostic and therapeutic management of hepatitis C-related hepatocellular carcinoma in HCV-HIV co-infected patients.

Diagnosis

Carcinogenesis

The development of a neoplasm is a stepwise process that involves at least two or more genetic events cumulating in unrestrained cell growth, tissue invasion, and metastasis. Aberrant expression of cancer-related genes is one of the hallmarks of cancer cells and plays a role in carcinogenesis. These genetic changes are more often acquired from a combination of chemical, physical or biological agent. HCC displays numerous genetic abnormalities combined to activate upregulators of cell proliferation and inactivate downregulators [18,22,31]. HCV related carcinogenesis is mediated by host-induced immunologic response[32]. Viral replication does not lead to cellular death: the virus tends to harbor in the endoplasmic reticulum of the hepatocytes where it induces synthesis of the viral proteins, such as NS5A. The NS5A protein inhibits the p53 pathway, ending in the upregulation of cell cycles and cellular proliferation[22,31,33]. An increased cellular replication conducts to dysplastic nodule (DN), normal-appearing hepatocytes with only foci of cellular atypia, and HCC, characterized by an excess of mediator factors produced by tumor cells, which contribute to create an abnormal vascular network within the nodule, ending in hypovascularized regions which, in turn, become necrotic[31,34-36].

Noninvasive Techniques

The atypical vascular profile of HCC and hepatic nodules (HN) can be detected with the ultrasounds (US) or with other noninvasive techniques such as magnetic resonance imaging (MRI) and contrast-enhanced computed tomography (CT)[37,38].

US are less expensive, radiation-free, techniques. Abdominal US are recommended at 6-month intervals in cirrhotic patients[39,40]. However, the diagnosis of the smaller HCC nodules it might be often difficult to differentiate benign from malignant lesions in the context of the smaller HCC nodules. Moreover, abdominal US have limited sensitivity and they are not only operator- but also patient-dependent[41,42]. MRI allows the differentiation between tumor and normal liver parenchyma using magnetic fields. The sensitivity and specificity (90% and 95%) of standard MRI with contrast media are high for the detection of HCC bigger than 2 cm in diameter[19,43,44]. HCC classically appears as a hyper-attenuated lesion in the arterial phase in a CT scan. This technique is largely used to make that the radiological diagnosis of HCC after a liver nodule is detected on US and has high specificity but low sensitivity for detecting HCC[19,45,46].

Biomarker

Routinely tested biomarkers could be used for diagnosis and prognostic evaluations. Several studies and guidelines suggest that combining US and A-fetoprotein (AFP), lecithin bound AFP to total AFP ratio (AFP-L3), and des-gamma-carboxy-prothrombin (DCP), is a sufficient surveillance[47]. A-fetoprotein (AFP) has been used for several decades as a serum marker for the detection of HCC[48]. Sensitivity and specificity of AFP have been evaluated with variable results[44,49]. However, AFP levels can be falsely raised in patients who have active hepatitis but no evidence of HCC. Moreover, only a proportion of patients with HCC have elevated AFP serum levels[50]. Serum liver enzymes such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and γ-glutamyl-trans-

ferase (GGT), have been extensively evaluated in association with liver damage. Hie-Won et al[48] report that the elevation of serum GGT level could potentially be used as a prospective biomarker of the long-term risk of developing HCC. Serum IL-17 and osteopontin levels have been reported to be elevated in HCC patients; however, the diagnostic accuracy for either marker was lower or similar than AFP. Due to the sensibility or specificity limitation of AFP and other markers, new biomarkers are in development. Several authors reported about noninvasive and molecular methods to detect and monitor tumors. A cluster of three circulating (serum or plasmatic) long non-coding RNA – lncRNAs (LINC00152, RP11-160H22.5, XLOC014172), determined by qRT-PCR, may act as novel biomarkers for acting as fingerprint in HCC[51]. De Mattia et al[52] identified some genetic biomarkers, like five polymorphisms that may interact, contributing to predict the risk of developing a HCC. MicroRNAs (miRNAs) received particular attention as potential biomarkers. Differences in miRNA expression patterns have been found in several malignant conditions like HCC, but also inflammatory conditions might influence the miRNA levels[53-55]. Several authors[51,56-59] reported a broad spectrum of changes in microRNAome. Other microRNAs, such as miR454, could be even used as prognostic factors[60]. Circulating tumor DNA (ctDNA) consists in extracellular nucleic acid fragments released into plasma by tumor cells for an active and passive release of DNA. DNA methylation is an epigenetic regulator that usually results in gene silencing; however, there is an increase of this process early in some human tumors[61,62]. HCC-specific methylation markers showed a high correlation among the methylation profiles of HCC and DNA circulating tumor DNA (ctDNA). Xu et al[61] used ctDNA samples from a large cohort of 1,098 HCC patients to build a diagnostic prediction model that showed its high diagnostic specificity and sensitivity, which was highly correlated with tumor burden, treatment response, and stage. Further studies are required to establish the capability of these biomarkers to discriminate between inflammation liver diseases and cancer.

Staging

There are a lot of staging systems for HHC (Okuda classification), French classification, Cancer of the Liver Italian Program (CLIP) score and Barcelona Clinic Liver Cancer (BCLC) system, CUPI score, Japan Integrated Staging (JIS) and TNM, but none of them is universally accepted[63]. However, the most widely endorsed staging is the BCLC system, characterized by several parameters as tumor burden, functional status, and liver function. Moreover, in contrast with other staging systems, BCLC relates the stage of the disease to a specific treatment strategy[64,65]. The BCLC divided patients into four groups: stage 0 corresponds to early HCC, and the optimal treatment is surgery. Stage A is early HCC, a condition where radical therapies like resection, liver transplantation or percutaneous treatments are at their maximum effectiveness. Stage B is intermediate HCC. Patient with this condition may benefit from chemoembolization. Stage C is advanced HCC, when optimal treatment is represented by new chemical agents, while stage D is end-stage disease, when no other treatment than symptomatic therapy is suggested[63,66,67].

HCC in HIV Infected

HCC prevalence rate in HIV positive patients is higher than the general population and current evidence suggests that in HIV-infected patients a six-fold higher development risk of HCC has been reported[17,25].

In 2017 FDA and EMA agreed that every single person infected with HCV needs to be treated with Direct-Acting Antivirals (DAAs), and it was considered a huge step forward in the direction of the eradication of the HCV infection. However, later in this same year we had the first reports about HCCs appearance after completion of a treatment with DAAs. Therefore, it is still discussed if DAAs and the achievement of sustained virologic response (SVR) are enough to stop the development of HCC[16,26-30].

Moreover, people living with HIV (PLWH) may have higher HCC-related morbidity and mortality, with a younger onset age and a worse prognosis[17,68]. The role of HIV on cancer has long been investigated and HIV infection is involved in progression from liver cirrhosis to HCC not only through immunosuppression, but also with a direct effect of HIV on hepatic stellate cells. These cells may play an important role in the progression of liver fibrosis[20]. Furthermore, HIV replication may induce miR-122 synthesis, which is essential for HCV replication[63]. Some investigations highlight that HIV acts with a direct liver toxicity through the predominant $CD8^+$ cell response, mainly mediated by pro-inflammatory cytokines, which also stimulate fibrosis; moreover, HIV also cause an indirect liver damage because of its ther-

apy. As a matter of fact, some antiretroviral drugs have an intrinsic hepatotoxicity.

Treatment

A high number of HIV-infected patients received treatment for HCC. Different therapeutic options are available depending on several factors such as HCC stage, liver functions, comorbidities and they have been divided into three groups: potentially curative, proven effective but not curative, and unproven or ineffective therapy. In HIV-infected patients, surgical options are preferred compared to non-surgical therapies. However, a multidisciplinary team is necessary for a correct management.

Surgical Treatment

The evaluation of liver functional reserve is an essential step before liver surgery. In addition, Makuuchi's selection criteria – presence of ascites, serum bilirubin and ICG retention rate at 15 min (ICGR15) – must be considered[69-72]. Poor resection significantly increases the risk of early recurrence of cancer, so it is imperative to make the right choice. Trans-arterial chemoembolization (TACE) should be offered to patients with preserved function and no vascular invasion or extra-hepatic spread (BCLC tumor stage 0)[73]. HCC usually develops in patients with chronic hepatitis (HCV or HBV related) or cirrhosis, who are at risk of hepatic failure in case of insufficient liver remnant volume after liver surgery; in these patients, the portal vein embolization (PE) technique may prevent hepatic failure and improve survival[74]. Surgical resection is the treatment of choice in solitary tumors ≤5 cm up to three nodules ≤3 cm, without vascular invasion or extrahepatic spread, with preserved hepatic function and absence of portal hypertension. In patients with portal venous invasion, the area supplied by the portal vein branches should be removed. Survival of patients with early HCC amounts to 41-74% at 5 years after resection, while vascular invasion is a poor indicator of long-term survival[19,75-78]. Major perioperative complications may include hemorrhage and intra-abdominal abscesses, while postoperative complications could be mainly hepatic failure and disseminated intravascular coagulation[79,80].

Liver Transplantation

Liver transplantation offers an even better rate of long-term survival after 5 years for many patients with HCC. PLWH often present HCC in an advanced stage, reducing the available therapeutic choices[19,25]. Moreover, just a few years ago, HIV infection was considered an exclusion criterion for liver transplantation, exactly because PLWH only show symptoms of disease in an advanced stage[81]. In recent years, liver transplantation has been performed on patients with HIV infection and HCC[13,25,75,82]. Mazzaferro et al[83] defined in 1996 the Milan's criteria for eligibility for transplantation in HIV-free patients[83-85]. However, the current criteria for liver transplantation in PLWH do not differ from those indicated for HIV-negative individuals, except for an undetectable HIV viral load and a $CD4^+$ cell count higher than 150 cells/ml, the baseline criteria for liver transplantation in HIV-positive people[25,84,86,87].

Medical Treatment

ART, when correctly taken, significantly reduces the rate of hepatic failure events by 28-41%, so cART should be administered to HIV/HCV-coinfected patients to lower the risk of end-stage liver disease[88]. To date, advanced HCC in compensated patients are treated with Sorafenib, the only systemic therapy with a documented improvement in overall survival[73,89-91]. Sorafenib is a tyrosine kinase inhibitor which use in advanced HCC was approved in 2008, based on two multicenter trials: SHARP and Asia-Pacific. Recent studies[11,86] have described the use of Sorafenib for HCC in PLWH and found a comparable efficacy and reasonable safety profile when compared HIV-negative patients. Molecule-targeted therapies represent a new promising field in advanced HCC therapies and tyrosine kinase inhibitors and monoclonal antibodies represent currently established treatments. Ras/Raf/MEK/ERK (MAPK), Wnt/catenin and Phospho-inositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathways are the most evaluated molecular intracellular targets[73]. The development of immune inhibitors for advanced HCC patients is an interesting area of study. Only two drugs are currently being tested in phase 3 trials: lenvatinib, an anti-angiogenic molecule acting as a multi-kinase inhibitor, and nivolumab, an immune checkpoint inhibitor with an overall response rate of 15% and a promising favorable survival data in a small cohort of patients affected with HCC[92]. Unfortunately, no HIV patients were included in the trials.

Conclusions

HCC is a major worldwide public health problem due to its rising incidence and high morta-

lity in both developing and developed countries. This is especially true in PLWH co-infected with HCV, whose cancers present in advanced stage. Early diagnosis is crucial, so PLWH at risk of developing HCC should be regularly checked to find the cancer in an early stage. When an HCC is detected at an early stage, curative treatments as surgery or liver transplantation are possible. A pharmacological approach in advanced stage cancers is possible with the new experimental drugs. Unfortunately, knowledge is limited and comes from case reports and retrospective studies. Further studies, especially multicenter ones, are needed in order to define the most appropriate, evidence-based therapeutic approach to PLWH suffering from HCC. It also appears necessary to develop appropriate care guidelines for PLWH that differ from those applicable to non-HIV infected patients, because of their cancers being more aggressive.

Conflict of interest

The authors declare no conflicts of interest.

References

1) Castronuovo D, Pinzone MR, Moreno S, Cacopardo B, Nunnari G. HIV infection and bone disease: a review of the literature. Infect Dis Trop Med 2015; 1:e116.
2) Celesia BM, Nigro L, Pinzone MR, Coco C, La Rosa R, Bisicchia F, Mavilla S, Gussio M, Pellicanò G, Milioni V, Palermo F, Russo R, Mughini MT, Martellotta F, Taibi R, Cacopardo B, Nunnari G. High prevalence of undiagnosed anxiety symptoms among HIV-positive individuals on cART: a cross-sectional study. Eur Rev Med Pharmacol Sci 2013; 17: 2040-2046.
3) Montrucchio C, Biagini R, Alcantarini C, Calcagno A, Barco A, Ferrara M, Milesi M, Costa C, Trentalange A, Trunfio M, Tettoni MC, Grosso Marra W, D'Ascenzo F, Ballocca F, Lonni E, Gili S, Vai D, Imperiale D, Gaita F, Bonora S, Di Perri G. Cardiovascular risk and neurocognitive deficits in HIV-positive individuals. Infect Dis Trop Med 2017; 3: e370.
4) Yanik EL, Katki HA, Engels EA. Cancer risk among the HIV-infected elderly in the United States. AIDS 2016; 30: 1663-1668. doi: 10.1097/QAD.0000000000001077
5) Visalli G, Bertuccio MP, Currò M, Pellicanò G, Sturniolo G, Carnevali A, Spataro P, Ientile R, Picerno I, Cavallari V, Piedimonte G. Bioenergetics of T cell activation and death in HIV type 1 infection. AIDS Res Hum Retroviruses 2012; 28: 1110-1118. doi: 10.1089/AID.2011.0197
6) Lai V, Zizi B, Vadini F, Calia GM, Bagella P, Fiore V, Peruzzu F, Caruana G, Babudieri S, Mura MS. FIB-4 values and neurocognitive function in HIV-infected patients without hepatic coinfections. Infect Dis Trop Med 2016; 2: e293.
7) Visalli G, Paiardini M, Chirico C, Cervasi B, Currò M, Ferlazzo N, Bertuccio MP, Favaloro A, Pellicanò G, Sturniolo G, Spataro P, Ientile R, Picerno I, Piedimonte G. Intracellular accumulation of cell cycle regulatory proteins and nucleolin re-localization are associated with pre-lethal ultrastructural lesions in circulating T lymphocytes: the HIV-induced cell cycle dysregulation revisited. Cell Cycle 2010; 9:b2130-2140. doi: 10.4161/cc.9.11.11754
8) Trovato M, Ruggeri RM, Sciacchitano S, Vicchio TM, Picerno I, Pellicanò G, Valenti A, Visalli G. Serum interleukin-6 levels are increased in HIV-infected patients that develop autoimmune disease during long-term follow-up. Immunobiology 2017 Oct 16. pii: S0171-2985(17)30180-8. doi: 10.1016/j.imbio.2017.10.039. [Epub ahead of print]
9) Scarpino M, Santoro M, Pellicanò G. HIV infection and kidney disease: literature review. Infect Dis Trop Med 2015; 1: e195.
10) Bagella P, Fiore V, Caruana G, Madeddu G. Editorial - Non AIDS-defining malignancies: a new epidemic in HIV-infected population for the upcoming decades? Eur Rev Med Pharmacol Sci 2017; 21: 4744-4745.
11) Berretta M, Martellotta F, Di Francia R, Spina M, Vaccher E, Balestrieri L, Borsatti E, Bearz A, De Paoli P, Tirelli U. Clinical presentation and outcome of non-AIDS defining cancers, in HIV-infected patients in the ART-era: the Italian Cooperative Group on AIDS and tumors activity. Eur Rev Med Pharmacol Sci 2015; 19: 3619-3634.
12) Berretta M, Zanet E, Di Benedetto F, Simonelli C, Bearz A, Morra A, Bonanno S, Berretta S, Tirelli U. Unusual presentation of metastatic hepatocellular carcinoma in an HIV/HCV coinfected patient: case report and review of the literature. Tumori 2008; 94: 589-591. doi: 10.1700/371.4344
13) Di Benedetto F, Tarantino G, Ercolani G, Baccarani U, Montalti R, De Ruvo N, Berretta M, Adani GL, Zanello M, Tavio M, Cautero N, Tirelli U, Guaraldi G. Multicenter Italian Experience in Liver Transplantation for Hepatocellular Carcinoma in HIV-Infected Patients. Oncologist 2013; 18: 592-599.
14) Berretta S, Fisichella R, Spartà D, Lleshi A, Nasti G. Primary liver cancer: clinical aspects, prognostic factors and predictive response to therapy. WCRJ 2015; 2:e561.
15) Carbone A, Vaccher E, Gloghini A, Pantanowitz L, Abayomi A, de Paoli P, Franceschi S. Diagnosis and management of lymphomas and other cancers in HIV-infected patients. Nat Rev Clin Oncol 2014; 11: 223-238. doi: 10.1038/nrclinonc.2014.31
16) Fiore V, Vidili G, Bagella P, Lobrano G, Muredda AA, Caruana G, Babudieri S, Madeddu G. Hepatocellular carcinoma development in a patient with HCV infection after eradication with direct-acting antiviral agents. WCRJ 2017; 4:e833.
17) Nunnari G, Berretta M, Pinzone MR, Di Rosa M, Berretta S, Cunsolo G, Malaguarnera M, Cosentino S, De Paoli P, Schnell JM, Cacopardo B. Hepatocellular

carcinoma in HIV positive patients. Eur Rev Med Pharmacol Sci 2012; 16: 1257-1270.

18) Canzonieri V, Alessandrini L, Caggiari L, Perin T, Berretta M, Cannizzaro R, De Re V. Hepatocellular carcinoma: an overview of clinico-pathological and molecular perspectives. WCRJ 2015; 2: e485.

19) Bellissimo F, Pinzone MR, Cacopardo B, Nunnari G. Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol 2015; 21: 12003-12021. doi: 10.3748/wjg.v21.i42.12003

20) Tuyama AC, Hong F, Saiman Y, Wang C, Ozkok D, Mosoian A, Chen P. Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology 2010; 52: 612-622. doi: 10.1002/hep.23679

21) Crissien AM, Frenette C. Current management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) 2014; 10: 153-161.

22) Balogh J, Victor D, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM, Monsour HP. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma 2016; 3: 41-53. doi: 10.2147/JHC.S61146

23) El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139: 817. doi: 10.7326/0003-4819-139-10-200311180-00009

24) Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, Kawashima T. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-1801. doi: 10.1056/NEJM199306243282501

25) El Dika I, Harding JJ, Abou-Alfa GK. Hepatocellular carcinoma in patients with HIV. Curr Opin HIV AIDS 2016; 12: 20-25. doi: 10.1097/COH.0000000000000335

26) D'Arminio Monforte A, Cozzi-Lepri A, Ceccherini-Silberstein F, De Luca A, Caputo Lo S, Castagna A, Mussini C, Cingolani A, Tavelli A, Shanyinde M, Gori A, Girardi E, Andreoni M, Antinori A, Puoti M. Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: data from the icona cohort. PLoS One 2017; 12: e0177402. doi: 10.1371/journal.pone.0177402

27) Rinaldi L, Di Francia R, Coppola N, Guerrera B, Imparato M, Monari C, Nevola R, Rosato V. Hepatocellular carcinoma in HCV cirrhosis after viral clearance with direct acting antiviral therapy: preliminary evidence and possible meanings. WCRJ 2016; 3: e748.

28) Berretta M, Di Francia R, Di Benedetto F, Tirelli U. New entities in the treatment of hepatocelllar carcinoma: HIV-positive and elderly patients. WCRJ 2015; 2:e558.

29) Kawaguchi T, Ide T, Koga H, Kondo R, Miyajima I, Arinaga-Hino T, Kuwahara R, Amano K, Niizeki T, Nakano M, Kuromatsu R, Torimura T. Rapidly growing hepatocellular carcinoma after direct-acting antiviral treatment of chronic hepatitis C. Clin J Gastroenterol 2017 Oct 29. doi: 10.1007/s12328-017-0789-1. [Epub ahead of print]

30) European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 2016; 66: 153-194. doi: 10.1016/j.jhep.2016.09.001

31) Ghouri Y, Mian I, Rowe J. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog 2016; 16: 1. doi: 10.4103/jcar.JCar_9_16

32) ao F, Liu M, Zhang Q-Z, Hao R (2016) PHACTR4 regulates proliferation, migration and invasion of human hepatocellular carcinoma by inhibiting IL-6/Stat3 pathway. Eur Rev Med Pharmacol Sci 20: 3392-3399.

33) Majumder M, Steele R, Ray R. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol 2001; 75: 1401-1407.

34) Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 2013; 144: 512-527. doi: 10.1053/j.gastro.2013.01.002

35) Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 2011; 8: 292-301. doi: 10.1038/nrclinonc.2011.30

36) Zhang Y-X, Jing B-Q, Ou Y, Zhao L, Xie Q, Zhang Y-X (2017) Experimental study on the prevention of liver cancer angiogenesis via miR-126. Eur Rev Med Pharmacol Sci 21: 5096-5100.

37) Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, Lok AS. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl 2005; 11: 281-289. doi: 10.1002/lt.20357

38) Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008; 247: 311-330. doi: 10.1148/radiol.2472061331

39) Choi BI. Hepatocarcinogenesis in liver cirrhosis: imaging diagnosis. J Korean Med Sci 1998; 13: 103-116.

40) Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022. doi: 10.1002/hep.24199

41) Wu W, Chen M-H, Sun M, Yan K, Yang W, Li J-Y. Contrast-enhanced ultrasound of hepatocarcinogenesis in liver cirrhosis. Chin Med J 2012; 125: 3104-3109.

42) Matsui O, Kadoya M, Kameyama T, Yoshikawa J, Takashima T, Nakanuma Y, Unoura M, Kobayashi K, Izumi R, Ida M. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology 1991; 178: 493-497. doi: 10.1148/radiology.178.2.1846240

43) Ito K. Hepatocellular carcinoma: conventional MRI findings including gadolinium-enhanced dy-

namic imaging. Liver Lesions 2006; 58: 186-199. doi: https://doi.org/10.1016/j.ejrad.2005.11.039

44) Cadier B, Bulsei J, Nahon P, Seror O, Laurent A, Rosa I, Layese R, Costentin C, Cagnot C, Durand-Zaleski I, Chevreul K. Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States. Hepatology 2007; 65: 1237-1248. doi: 10.1002/hep.28961

45) Kim SH, Choi BI, Lee JY, Kim SJ, So YH, Eun HW, Lee JM, Han JK. Diagnostic accuracy of multi-/single-detector row ct and contrast-enhanced mri in the detection of hepatocellular carcinomas meeting the Milan criteria before liver transplantation. Intervirology 2008; 51(suppl 1): 52-60.

46) Hayashi M, Matsui O, Ueda K, Kawamori Y, Gabata T, Kadoya M. Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology 2002; 225: 143-149. doi: 10.1148/radiol.2251011298

47) Chaiteerakij R, Addissie B, Roberts, LR. Update on biomarkers of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2013; 13: 237-245. doi: https://doi.org/10.1016/j.cgh.2013.10.038

48) Hann H-W, Wan S, Xing J, Chen B, Yang H. Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients. PLoS One 2012; 7: e47687. doi: 10.1371/journal.pone.0047687

49) Ashida R, Okamura Y, Ohshima K, Kakuda Y, Uesaka K, Sugiura T, Ito T, Yamamoto Y, Sugino T, Urakami K, Kusuhara M, Yamaguchi K. CYP3A4 gene is a novel biomarker for predicting a poor prognosis in hepatocellular carcinoma. Cancer Genomics Proteomics 2017; 14: 445-453. doi: 10.21873/cgp.20054

50) Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol 2012; 39: 410-433. doi: https://doi.org/10.1053/j.seminoncol.2012.05.001

51) Yuan W, Sun Y, Liu L, Zhou B, Wang S, Gu D. Circulating LncRNAs serve as diagnostic markers for hepatocellular carcinoma. Cell Physiol Biochem 2017; 44: 125-132.

52) De Mattia E, Cecchin E, Polesel J, Bignucolo A, Roncato R, Lupo F, Crovatto M, Buonadonna A, Tiribelli C, Toffoli G. Genetic biomarkers for hepatocellular cancer risk in a caucasian population. World J Gastroenterol 2017; 23: 6674-6684. doi: 10.3748/wjg.v23.i36.6674

53) Schütte K, Schulz C, Link A, Malfertheiner P. Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World J Hepatol 2015; 7: 139-149. doi: 10.4254/wjh.v7.i2.139

54) Tan Y, Ge G, Pan T, Wen D, Gan J. A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. PLoS One 2014; 9: e105192. doi: 10.1371/journal.pone.0105192

55) Giordano S, Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology 2013; 57: 840-847. doi: 10.1002/hep.26095

56) Qi P, Cheng SQ, Wang H, Li N, Chen YF, Gao CF. Serum MicroRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One 2011; 6: e28486. doi:10.1371/journal.pone.0028486

57) Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2005; 25: 2537-2545 doi: 10.1038/sj.onc.1209283.

58) Lu J, Getz G, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Jacks T, Horvitz HR MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838. doi: 10.1038/nature03702.

59) Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, Qin L, Wu X, Zheng Y, Yang Y, Tian W, Zhang Q, Wang C, Zhang Q, Zhuang S-M, Zheng L, Liang A, Tao W, Cao X. Identification of miRNomes in human liver and hepatocellular carcinoma reveals mir-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011; 19: 232-243. doi: 10.1016/j.ccr.2011.01.001

60) Zhou L, Qu YM, Zhao XM, Yue ZD (2016). Involvement of miR-454 overexpression in the poor prognosis of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 20: 825-829.

61) Xu RH, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X, Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017; 16: 1155-1161. doi: 10.1038/nmat4997

62) Stroun M, Maurice P, Vasioukhin V, Lyautey J, Lederrey C, Lefort F, Rossier A, Chen XQ, Anker P. The origin and mechanism of circulating DNA. Ann N Y Acad Sci 2006; 906: 161. doi: 10.1111/j.1749-6632.2000.tb06608.x

63) PonS F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB 2005; 7: 35-41. doi: https://doi.org/10.1080/13651820410024058

64) Sherman M. Hepatocellular carcinoma: screening and staging. Clin Liver Dis 2011; 15: 323-324. doi: 10.1016/j.cld.2011.03.003

65) Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338. doi: 10.1055/s-2007-1007122

66) Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, Rapaccini GL, Gasbarrini G. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005; 54: 411-418. doi: 10.1136/gut.2004.048124

67) Barrat A, Askari F. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005; 41: 707-715. doi: 10.1002/hep.20636

68) Pinato DJ, Dalla Pria A, Sharma R, Bower M. Hepatocellular carcinoma: an evolving challenge in viral hepatitis and HIV coinfection. AIDS 2017; 31: 603-611. doi: 10.1097/qad.0000000000001422

69) Makuuchi M, Kosuge T, Takayama T, Yamazaki S, Kakazu T, Miyagawa S, Kawasaki S. Surgery for small liver cancers. Semin Surg Oncol 1993; 9: 298-304. doi: 10.1002/ssu.2980090404

70) Imamura H, Seyama Y, Kokudo N, Maema A, Sugawara Y, Sano K, Takayama T, Makuuchi M. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg 2013; 138: 1198. doi: 10.1001/archsurg.138.11.1198

71) Hasegawa K, Kokudo N, Imamura H, Matsuyama Y, Aoki T, Minagawa M, Sano K, Sugawara Y, Takayama T, Makuuchi M. Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg 2005; 242: 252. doi: 10.1097/01.sla.0000171307.37401.db

72) Mandorfer M, Schwabl P, Steiner S, Reiberger T, Peck-Radosavljevic M. Advances in the management of HIV/HCV coinfection. Hepatol Int 2016; 10: 424-435. doi: 10.1007/s12072-015-9691-4

73) Rinninella E, Cerrito L, Spinelli I, Cintoni M, Mele MC, Pompili M, Gasbarrini A. Chemotherapy for hepatocellular carcinoma: current evidence and future perspectives. J Clin Transl Hepatol 2017; 5: 235-248. doi: 10.14218/JCTH.2017.00002

74) Armengol C, Sarrias MR, Sala M. Hepatocellular carcinoma: present and future. Med Clin (Barc) 2017 Oct 30. pii: S0025-7753(17)30717-0. doi: 10.1016/j.medcli.2017.08.010. [Epub ahead of print]

75) Di Benedetto F, De Ruvo N, Berretta M, Masetti M, Montalti R, Di Sandro S, Ballarin R, Codeluppi M, Guaraldi G, Gerunda GE. Hepatocellular carcinoma in HIV patients treated by liver transplantation. Eur J Surg Oncol 2007; 34: 422-427. doi: 10.1016/j.ejso.2007.05.004

76) Yamazaki S, Takayama T, Moriguchi M, Mitsuka Y, Okada S, Midorikawa Y, Nakayama H, Higaki T. Criteria for drain removal following liver resection. Br J Surg 2012; 99: 1584-1590. doi: 10.1002/bjs.8916

77) Arii S, Tanaka J, Yamazoe Y, Minematsu S, Morino T, Fujita K, Maetani S, Tobe T (1992) Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy. Cancer 1992; 69: 913-919. doi: 10.1002/1097-0142(19920215)69:43.0.CO; 2-T

78) D'Amico G, Tarantino G, Ballarin R, Serra V, Pecchi AR, Guaraldi G, Di Benedetto F. Liver resection for HCC in HIV-infected patients: a single center experience. WCRJ 2015; 2: e490.

79) Nakayama H, Takayama T, Okubo T, Higaki T, Midorikawa Y, Moriguchi M, Aramaki O, Yamazaki S. Subcutaneous drainage to prevent wound infection in liver resection: a randomized controlled trial. J Hepatobiliary Pancreat Sci 2014; 21: 509-517. doi: 10.1002/jhbp.93

80) Hayashi Y, Takayama T, Yamazaki S, Moriguchi M, Ohkubo T, Nakayama H, Higaki T. Validation of perioperative steroids administration in liver resection: a randomized controlled trial. Ann Surg 2011; 253: 50-55. doi: 10.1097/SLA.0b013e318204b6bb

81) Berretta M, Garlassi E, Cacopardo B, Cappellani A, Guaraldi G, Cocchi S, de Paoli P, Lleshi A, Izzi I, Torresin A, Pietrangelo A, Ferrari M, Bearz A, Berretta S, Nasti G, Di Benedetto F, Balestreri L, Tirelli U, Ventura P. Hepatocellular carcinoma in HIV-infected patients: check early, Treat Hard. Oncologist 2011; 16: 1258-1269.

82) Di Benedetto F, De Ruvo N, Berretta M, Masetti M, Montalti R, Di Sandro S, Quintini C, Codeluppi M, Tirelli U. Don't deny liver transplantation to hiv patients with hepatocellular carcinoma in the highly active antiretroviral therapy era. J Clin Oncol 2006; 24: e26-e27. doi: 10.1200/JCO.2006.06.1374

83) Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver Transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-700. doi: 10.1056/NEJM199603143341104

84) Cillo U, Vitale A, Bassanello M, Boccagni P, Brolese A, Zanus G, Burra P, Fagiuoli S, Farinati F, Rugge M, D'Amico DF. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 2004; 239: 150-159. doi: 10.1097/01.sla.0000109146.72827.76

85) Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Sem Liver Dis 1999; 19: 311-322.

86) Gelu-Simeon M, Sobesky R, Haïm-Boukobza S, Ostos M, Teicher E, Fontaine H, Salmon-Ceron D, Meyer L, Trinchet J-C, Paule B, Samuel D, Lewin M, Duclos-Vallée J-C. Do the epidemiology, physiological mechanisms and characteristics of hepatocellular carcinoma in HIV-infected patients justify specific screening policies? AIDS 2014; 28: 1379-1391. doi: 10.1097/QAD.0000000000000300

87) Guerrini GP, Berretta M, Tarantino G, Magistri P, Pecchi A, Ballarin R, Di Benedetto F (2017) Multimodal oncological approach in patients affected by recurrent hepatocellular carcinoma after liver transplantation. Eur Rev Med Pharmacol Sci 21: 3421-3435.

88) Anderson JP, Tchetgen EJ, Lo Re V, Tate JP, Williams PL, Seage GR, Horsburgh CR, Lim JK, Goetz MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Klein MB, Justice AC. Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and Hepatitis C viruscoinfected veterans. Clin Infect Dis 2014; 58: 719-727. doi: 10.1093/cid/cit779

89) Berretta M, Caraglia M, Martellotta F, Zappavigna S, Lombardi A, Fierro C, Atripaldi L, Muto T, Valente D, de Paoli P, Tirelli U, Di Francia R. Drug-drug interactions based on pharmacogenetic profile between highly active antiretroviral therapy and antiblastic chemotherapy in cancer patients with HIV Infection. Front Pharmacol 2016; 7: 71. doi: 10.3389/fphar.2016.00071

90) Berretta M, Di Benedetto F, Maso LD, Cacopardo B, Nasti G, Facchini G, Bearz A, Spina M, Garlassi E, De Re V, Fiorica F, Lleshi A, Tirelli U. Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients. Anticancer Drugs 2013; 24: 212-218. doi: 10.1097/CAD.0b013e32835c032f

91) Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, de Oliveira AC, Santoro A, Raoul J-L, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz J-F, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390. doi: 10.1056/NEJMoa0708857

92) El-Khoueiry AB, Melero I, Crocenzi TS, Welling TH, Yau TC, Yeo W, Chopra A, Grosso J, Lang L, Anderson J, Dela Cruz CM, Sangro B. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol 2015; 33: LBA101. doi: 10.1200/jco.2015.33.18_suppl.lba101

DOI: 10.26355/eurrev_201712_14035